Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Mammoth Biosciences develops CRISPR-based gene-editing therapies and diagnostic tests for patients and pharmaceutical partners.
Mammoth Biosciences is a biotechnology company built on CRISPR, the gene-editing tool that works like molecular scissors to find and cut specific pieces of DNA. The company uses that tool in two ways: it is developing medicines that edit genes inside patients to treat disease, and it makes diagnostic tests that detect infections and other conditions by spotting tiny amounts of genetic material.
The therapeutics side is the big bet. Mammoth is designing CRISPR-based treatments aimed at serious diseases, and it works with large pharmaceutical partners who bring money, expertise, and reach that a small biotech cannot muster alone. The economics of drug development are brutal: years of research and clinical trials before a single dollar of product revenue arrives, which is why partnerships matter so much. A partner can fund the work, share the risk, and take over commercialization if a therapy succeeds. The diagnostics side is closer to a real business today. Mammoth's tests are designed to be fast and usable outside a big lab, so a clinic or even a field setting could get an answer without shipping samples to a centralized facility. That is the same promise CRISPR diagnostics have held since the technology proved it could detect viruses quickly and cheaply.
The company's name comes from the woolly mammoth, a nod to the idea of bringing extinct things back — here, bringing back tools the body has lost or fixing broken genes. Mammoth carries real scientific credibility, but it is still a private, research-heavy company burning cash to chase approvals, so its future depends on whether its therapies and tests clear the long, expensive path from lab bench to patient.
Saved answer · last researched 15 Nov 2026